Oncology: clinical-trial pipeline
119,341 oncology trials are in ClinicalTrials.gov and the EU CTIS portal; 33,935 are not yet finished and 3,272 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 14,547 |
| Phase 2 | 8,421 |
| Phase 1 | 3,820 |
| Phase 3 | 2,784 |
| Phase 1/2 | 2,729 |
| Early phase 1 | 662 |
| Phase 2/3 | 488 |
| Phase 4 | 482 |
| Not stated | 2 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT06373211 | Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with… | Assistance Publique - Hôpitaux de Paris | Phase 2 | Recruiting | France |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Merck Sharp & Dohme LLC | Phase 2 | Active, not recruiting | Argentina, Australia, Canada, Chile +9 |
| NCT06304597 | Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy | University Medical Center Groningen | Phase 1 | Recruiting | Netherlands |
| NCT06178614 | A Study of JNJ-87890387 for Advanced Solid Tumors | Janssen Research & Development, LLC | Phase 1 | Recruiting | Spain, France, United States |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castra… | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Australia, Brazil, Canada, Chile +34 |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Argentina, Austria, Australia, Brazil +31 |
| NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physicia… | AstraZeneca | Phase 3 | Not yet recruiting | Austria, Australia, Belgium, Brazil +21 |
| NCT06120140 | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated… | Janssen Research & Development, LLC | Phase 2 | Active, not recruiting | Argentina, Brazil, China, Germany +6 |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | Consorzio Oncotech | Phase 2 | Recruiting | Spain, Italy |
| NCT05723562 | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | GlaxoSmithKline | Phase 2 | Active, not recruiting | Canada, Germany, Spain, France +6 |
| NCT05453903 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Janssen Research & Development, LLC | Phase 1 | Active, not recruiting | Australia, Canada, Germany, Spain +4 |
| NCT05384015 | Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung… | Fundacion GECP | Phase 2 | Active, not recruiting | Spain |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Janssen Research & Development, LLC | Phase 1/2 | Active, not recruiting | Canada, Germany, Spain, Israel +4 |
| NCT05057494 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic… | AstraZeneca | Phase 3 | Active, not recruiting | Australia, Czechia, Spain, France +3 |
| NCT05041842 | Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | UNICANCER | Phase 2 | Active, not recruiting | France |
| NCT04873362 | A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for… | Hoffmann-La Roche | Phase 3 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +27 |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | IDEAYA Biosciences | Phase 1 | Active, not recruiting | Australia, Germany, Spain, France +3 |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abir… | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Active, not recruiting | Australia, Belgium, China, Czechia +9 |
| NCT04644289 | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | AGO Research GmbH | Phase 2 | Recruiting | Germany |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cel… | Merck Sharp & Dohme LLC | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +21 |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Oncology clinical trials: 33,935 open, 3,272 in phase 3", https://arcadiumdata.io/clinical-trials/area/oncology/, data as of 2026-10-25.